Image For Activity Cover
ITLPEDUC2210 - CME/CMLE - The Molecular Biomarker Revolution in Metastatic NSCLC
Course Description

During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty will discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC.  In addition, they will address how to integrate next generation sequencing (NGS) into your biomarker testing workflows and optimize its use for patients.  Finally, they will share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients. 

 The activity offers 1.0 CME/CMLE credit. 

 The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. 

 
Credit Designation Statement 

 The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity. 

 ASCP designates this enduring material for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel. 

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time 

 
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line. 


Faculty/Authors

Diana N. Ionescu MD, FRCPC, FCAP
Consultant Pathologist and Medical Lead Anatomical Pathology
Medical Director BC Cervical Cancer Screening Laboratory
Medical Director Clinical Trials, BC Cancer Laboratories
Clinical Professor of Pathology, University of British Columbia
 
Doru Paul, MD, PhD
Attending Physician, Division of Hematology and Medical Oncology
Weill Cornell and New York Presbyterian Hospit 

CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online Educational Activity

Physician Competencies: Patient Care, Medical Knowledge  

Accreditation Statement:
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).

Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Review the Faculty Disclosures.
  3. Click Go to Course to view an overview of the modules in this course.
  4. Click Access to begin the course.
  5. Review the Educational Activity.
  6. Submit the course Evaluation.
  7. Enter the maximum number of credits offered and click Claim CME to register credit.

Faculty Disclosure

Technical Considerations

Release Date: 11/3/2022  
Review Date:
Expiration Date: 11/3/2025  

Course Objectives
Following completion of this activity, you will be able to:
  • Describe ongoing investigational efforts regarding emerging biomarkers in metastatic NSCLC

  • Utilize NGS to identify current and emerging biomarkers to predict response to personalized therapies for patients with metastatic NSCLC

  • Employ strategies for optimizing workflows and turnaround times for NGS

  • Discuss the science behind resistance mechanisms in patients with metastatic NSCLC

  • Recognize the use of emerging I-O combination therapies and potential biomarkers in patients with metastatic NSCLC

  • Develop ways to improve communication among pathologists, oncologists, and other members of the multidisciplinary lung cancer care team

Summary
Availability: On-Demand
Credit Offered:
1 CME/CMLE Credit
Powered By